433 related articles for article (PubMed ID: 22828169)
1. Treatment of hyperprolactinemia: a systematic review and meta-analysis.
Wang AT; Mullan RJ; Lane MA; Hazem A; Prasad C; Gathaiya NW; Fernández-Balsells MM; Bagatto A; Coto-Yglesias F; Carey J; Elraiyah TA; Erwin PJ; Gandhi GY; Montori VM; Murad MH
Syst Rev; 2012 Jul; 1():33. PubMed ID: 22828169
[TBL] [Abstract][Full Text] [Related]
2. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
3. Hyperprolactinemia: etiology, diagnosis, and management.
Mah PM; Webster J
Semin Reprod Med; 2002 Nov; 20(4):365-74. PubMed ID: 12536359
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety in the treatment of hyperprolactinemia: A systematic review and network meta-analysis.
Fachi MM; de Deus Bueno L; de Oliveira DC; da Silva LL; Bonetti AF
J Clin Pharm Ther; 2021 Dec; 46(6):1549-1556. PubMed ID: 34137053
[TBL] [Abstract][Full Text] [Related]
5. Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience.
Arduc A; Gokay F; Isik S; Ozuguz U; Akbaba G; Tutuncu Y; Berker D; Kucukler FK; Aydin Y; Guler S
J Endocrinol Invest; 2015 Apr; 38(4):447-53. PubMed ID: 25421155
[TBL] [Abstract][Full Text] [Related]
6. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis.
dos Santos Nunes V; El Dib R; Boguszewski CL; Nogueira CR
Pituitary; 2011 Sep; 14(3):259-65. PubMed ID: 21221817
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Laboratory Characteristics of Hyperprolactinemia in Children and Adolescents: National Survey.
Eren E; Törel Ergür A; İşgüven ŞP; Çelebi Bitkin E; Berberoğlu M; Şıklar Z; Baş F; Yel S; Baş S; Söbü E; Bereket A; Turan S; Sağlam H; Atay Z; Ercan O; Güran T; Atabek ME; Korkmaz HA; Kılınç Uğurlu A; Akıncı A; Döğer E; Şimşek E; Akbaş ED; Abacı A; Gül Ü; Acar S; Mengen Uçaktürk E; Yıldız M; Ünal E; Tarım Ö
J Clin Res Pediatr Endocrinol; 2019 May; 11(2):149-156. PubMed ID: 30396878
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis.
Zeng Y; Huang Q; Zou Y; Tan J; Zhou W; Li M
Front Endocrinol (Lausanne); 2023; 14():1027905. PubMed ID: 36761195
[TBL] [Abstract][Full Text] [Related]
10. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
11. Hyperprolactinemia: a 12-year retrospective study at gynecologic endocrinology unit, Siriraj Hospital.
Saejong R; Dangrat C; Techatrisak K; Angsuwatthana S; Rattanachaiyanont M; Tanmahasamut P
J Med Assoc Thai; 2013 Oct; 96(10):1247-56. PubMed ID: 24350404
[TBL] [Abstract][Full Text] [Related]
12. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
13. Current treatment issues in female hyperprolactinaemia.
Crosignani PG
Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):152-64. PubMed ID: 16288952
[TBL] [Abstract][Full Text] [Related]
14. Guidelines for the diagnosis and treatment of hyperprolactinemia.
Biller BM; Luciano A; Crosignani PG; Molitch M; Olive D; Rebar R; Sanfilippo J; Webster J; Zacur H
J Reprod Med; 1999 Dec; 44(12 Suppl):1075-84. PubMed ID: 10649814
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
16. [When and how should hyperprolactinemia be treated?].
Bachelot A; Courtillot C; Touraine P
Presse Med; 2005 Jun; 34(10):731-7. PubMed ID: 16026128
[TBL] [Abstract][Full Text] [Related]
17. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
18. New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline.
Moro M; Inada Y; Kojima M; Miyata H; Komatsu H; Torii R
Eur J Pharmacol; 1999 Feb; 368(1):57-66. PubMed ID: 10096770
[TBL] [Abstract][Full Text] [Related]
19. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
Webster J; Piscitelli G; Polli A; Ferrari CI; Ismail I; Scanlon MF
N Engl J Med; 1994 Oct; 331(14):904-9. PubMed ID: 7915824
[TBL] [Abstract][Full Text] [Related]
20. Hyperprolactinemia/Prolactinomas in the Postmenopausal Period: Challenges in Diagnosis and Management.
Pekić S; Medic Stojanoska M; Popovic V
Neuroendocrinology; 2019; 109(1):28-33. PubMed ID: 30347396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
